Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q2- Text added to 2016 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
AAV, absent, androgen, anniversary, appellate, Article, artificially, attempting, boxed, BRCA, Britain, ceftaroline, clearance, conceptually, Convertase, core, creation, CRPC, culture, customary, CXL, de, dermatology, device, diffuse, Egypt, enzalutamide, exceeded, expiry, extract, fell, forfeiture, fosamil, Francisco, furnish, germline, hematologic, holder, ICU, inoperable, Kexin, Lisbon, mCRPC, media, Medivation, meropenem, Minister, modest, molecule, move, neuromuscular, output, panel, Par, parliamentary, PARP, penalty, pidilizumab, predominantly, Prime, prioritization, prohibition, Proprotein, prostate, Psychopharmacologic, reallocated, refund, rehearing, reopen, saline, San, signaling, sNDA, stable, Subtilisin, talazoparib, Team, Treaty, TSRU, University, unrestricted, warning, watch, weighted, Xtandi, Zavicefta, Zinforo
Valuein 2016 Q2 filing- Value in 2016 Q3 filing
Original filings
Filing view